...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: Epigenetic Modifiers as Potential Therapeutic Targets in Diabetic Kidney Disease

Bear can you at least state if this is the best information we have on this subject?

"Additionally, an increase in eGFR of 3.4% (p=0.04 vs. baseline) was observed in these patients compared to a decrease of 5.9% in the placebo group. The changes in plasma ALP activity for apabetalone and placebo were -14.0% vs. -6.3%, respectively (p<0.05)"

https://www.resverlogix.com/upload/media_element/attachments/27/era-edta-2017-poster-albumin.pdf

Koo

Share
New Message
Please login to post a reply